Global Exosome Therapy Market
Global Exosome Therapy Market

Exosome Therapy Comprehensive Study by Type (Instrument, Reagent, Software), Application (Diagnostic, Therapeutic), Therapy (Immunotherapy, Chemotherapy, Gene Therapy), Exosome Type (Natural Exosome, Hybrid Exosome), End-User (Cancer Institute, Hospital, Diagnostic Center, Others) Players and Region - Global Market Outlook to 2027

Exosome Therapy Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 232 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Exosome Therapy Market Scope
Exosome therapy is a highly targeted, adaptable treatment for musculoskeletal injuries, osteoarthritis, and chronic pain. The ability of the cells to communicate can be hampered by genetic problems, chronic and degenerative diseases, and the natural aging process. Exosomes are designed to carry a variety of therapeutic payloads, including short interfering ribonucleic acids (RNAs), antisense oligonucleotides, chemotherapeutic drugs, and immunological modulators, to specific targets. Exosome vesicle-based liquid biopsy has the potential to be employed in the diagnosis and prognosis of cancer and other illnesses in patients.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledSistemic Ltd Aethlon Medical, Inc. (United States), Exosome Diagnostic, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Malvern Instruments Ltd (United Kingdom), System Biosciences, Inc (United States), NX Pharmagen (United States), Capricor Therapeutics, Inc. (United States), Exiqon A/S (Denmark) and NanoSomix, Inc (United States)
CAGR%


Some of the corporations' favorite market-exploration techniques include mergers and acquisitions, expansions, investments, new service launches, and collaborations. The company is giving its fair share of the company's expansion. The major key players like Sistemic Ltd Aethlon Medical, Inc., Exosome Diagnostic, Inc., Thermo Fisher Scientific, Inc., and Malvern Instruments Ltd are contributing their share to increasing the market growth.

Sistemic Ltd Aethlon Medical, Inc. (United States), Exosome Diagnostic, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Malvern Instruments Ltd (United Kingdom), System Biosciences, Inc (United States), NX Pharmagen (United States), Capricor Therapeutics, Inc. (United States), Exiqon A/S (Denmark) and NanoSomix, Inc (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Exosome Therapy market by Type (Instrument, Reagent and Software), by Application (Diagnostic and Therapeutic) and Region with country level break-up.

On the basis of application, segment is dominating the market in the year 2021

On the basis of geography, the market of Exosome Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.

In 2021, Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, announced the acquisition of an exosome manufacturing facility in Lexington, Massachusetts (US) by Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries.


Market Trend
  • Advanced New Technology Is Helping To Increase the Market Growth
  • Therapeutic Application has a large demand in the market

Market Drivers
  • The Rise in Investment in Pharmaceutical and R&D Department
  • Increase in the Potential Application of Exosomes in Cancer Diagnosis
  • Increase in Use of the Multifunctional Property of Exosome Therapy

Opportunities
  • Increasing Demand For Specialized Testing Services
  • Increasing manufacturers And Number of Hospitals in Developing Countries

Restraints
  • High-Cost Therapy, And Sometimes Causes Side Effects of the Medicines

Challenges
  • Required Professionals Employ For Growing the Market
  • Strict Government Regulations


Key Target Audience
Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors

Frequently Asked Questions (FAQ):

1. What are the key segments playing vital role in Exosome Therapy Market?
The Exosome Therapy study can be customized to meet your requirements. The market size breakdown by type [Instrument, Reagent and Software], by end use application [Diagnostic and Therapeutic].

2. How big is the Exosome Therapy Market?
The Exosome Therapy Market is gaining popularity and expected to see strong valuation by 2027.

Report Objectives / Segmentation Covered
By Type
  • Instrument
  • Reagent
  • Software
By Application
  • Diagnostic
  • Therapeutic
By Therapy
  • Immunotherapy
  • Chemotherapy
  • Gene Therapy

By Exosome Type
  • Natural Exosome
  • Hybrid Exosome

By End-User
  • Cancer Institute
  • Hospital
  • Diagnostic Center
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rise in Investment in Pharmaceutical and R&D Department
      • 3.2.2. Increase in the Potential Application of Exosomes in Cancer Diagnosis
      • 3.2.3. Increase in Use of the Multifunctional Property of Exosome Therapy
    • 3.3. Market Challenges
      • 3.3.1. Required Professionals Employ For Growing the Market
      • 3.3.2. Strict Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Advanced New Technology Is Helping To Increase the Market Growth
      • 3.4.2. Therapeutic Application has a large demand in the market
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Exosome Therapy, by Type, Application, Therapy, Exosome Type, End-User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Exosome Therapy (Value)
      • 5.2.1. Global Exosome Therapy by: Type (Value)
        • 5.2.1.1. Instrument
        • 5.2.1.2. Reagent
        • 5.2.1.3. Software
      • 5.2.2. Global Exosome Therapy by: Application (Value)
        • 5.2.2.1. Diagnostic
        • 5.2.2.2. Therapeutic
      • 5.2.3. Global Exosome Therapy by: Therapy (Value)
        • 5.2.3.1. Immunotherapy
        • 5.2.3.2. Chemotherapy
        • 5.2.3.3. Gene Therapy
      • 5.2.4. Global Exosome Therapy by: Exosome Type (Value)
        • 5.2.4.1. Natural Exosome
        • 5.2.4.2. Hybrid Exosome
      • 5.2.5. Global Exosome Therapy by: End-User (Value)
        • 5.2.5.1. Cancer Institute
        • 5.2.5.2. Hospital
        • 5.2.5.3. Diagnostic Center
        • 5.2.5.4. Others
      • 5.2.6. Global Exosome Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Australia
          • 5.2.6.2.6. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Exosome Therapy (Price)
      • 5.3.1. Global Exosome Therapy by: Type (Price)
  • 6. Exosome Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sistemic Ltd Aethlon Medical, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Exosome Diagnostic, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Malvern Instruments Ltd (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. System Biosciences, Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NX Pharmagen (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Capricor Therapeutics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Exiqon A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NanoSomix, Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Exosome Therapy Sale, by Type, Application, Therapy, Exosome Type, End-User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Exosome Therapy (Value)
      • 7.2.1. Global Exosome Therapy by: Type (Value)
        • 7.2.1.1. Instrument
        • 7.2.1.2. Reagent
        • 7.2.1.3. Software
      • 7.2.2. Global Exosome Therapy by: Application (Value)
        • 7.2.2.1. Diagnostic
        • 7.2.2.2. Therapeutic
      • 7.2.3. Global Exosome Therapy by: Therapy (Value)
        • 7.2.3.1. Immunotherapy
        • 7.2.3.2. Chemotherapy
        • 7.2.3.3. Gene Therapy
      • 7.2.4. Global Exosome Therapy by: Exosome Type (Value)
        • 7.2.4.1. Natural Exosome
        • 7.2.4.2. Hybrid Exosome
      • 7.2.5. Global Exosome Therapy by: End-User (Value)
        • 7.2.5.1. Cancer Institute
        • 7.2.5.2. Hospital
        • 7.2.5.3. Diagnostic Center
        • 7.2.5.4. Others
      • 7.2.6. Global Exosome Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Australia
          • 7.2.6.2.6. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Exosome Therapy (Price)
      • 7.3.1. Global Exosome Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Exosome Therapy: by Type(USD Million)
  • Table 2. Exosome Therapy Instrument , by Region USD Million (2016-2021)
  • Table 3. Exosome Therapy Reagent , by Region USD Million (2016-2021)
  • Table 4. Exosome Therapy Software , by Region USD Million (2016-2021)
  • Table 5. Exosome Therapy: by Application(USD Million)
  • Table 6. Exosome Therapy Diagnostic , by Region USD Million (2016-2021)
  • Table 7. Exosome Therapy Therapeutic , by Region USD Million (2016-2021)
  • Table 8. Exosome Therapy: by Therapy(USD Million)
  • Table 9. Exosome Therapy Immunotherapy , by Region USD Million (2016-2021)
  • Table 10. Exosome Therapy Chemotherapy , by Region USD Million (2016-2021)
  • Table 11. Exosome Therapy Gene Therapy , by Region USD Million (2016-2021)
  • Table 12. Exosome Therapy: by Exosome Type(USD Million)
  • Table 13. Exosome Therapy Natural Exosome , by Region USD Million (2016-2021)
  • Table 14. Exosome Therapy Hybrid Exosome , by Region USD Million (2016-2021)
  • Table 15. Exosome Therapy: by End-User(USD Million)
  • Table 16. Exosome Therapy Cancer Institute , by Region USD Million (2016-2021)
  • Table 17. Exosome Therapy Hospital , by Region USD Million (2016-2021)
  • Table 18. Exosome Therapy Diagnostic Center , by Region USD Million (2016-2021)
  • Table 19. Exosome Therapy Others , by Region USD Million (2016-2021)
  • Table 20. South America Exosome Therapy, by Country USD Million (2016-2021)
  • Table 21. South America Exosome Therapy, by Type USD Million (2016-2021)
  • Table 22. South America Exosome Therapy, by Application USD Million (2016-2021)
  • Table 23. South America Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 24. South America Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 25. South America Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 26. Brazil Exosome Therapy, by Type USD Million (2016-2021)
  • Table 27. Brazil Exosome Therapy, by Application USD Million (2016-2021)
  • Table 28. Brazil Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 29. Brazil Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 30. Brazil Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 31. Argentina Exosome Therapy, by Type USD Million (2016-2021)
  • Table 32. Argentina Exosome Therapy, by Application USD Million (2016-2021)
  • Table 33. Argentina Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 34. Argentina Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 35. Argentina Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 36. Rest of South America Exosome Therapy, by Type USD Million (2016-2021)
  • Table 37. Rest of South America Exosome Therapy, by Application USD Million (2016-2021)
  • Table 38. Rest of South America Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 39. Rest of South America Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 40. Rest of South America Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 41. Asia Pacific Exosome Therapy, by Country USD Million (2016-2021)
  • Table 42. Asia Pacific Exosome Therapy, by Type USD Million (2016-2021)
  • Table 43. Asia Pacific Exosome Therapy, by Application USD Million (2016-2021)
  • Table 44. Asia Pacific Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 45. Asia Pacific Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 46. Asia Pacific Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 47. China Exosome Therapy, by Type USD Million (2016-2021)
  • Table 48. China Exosome Therapy, by Application USD Million (2016-2021)
  • Table 49. China Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 50. China Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 51. China Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 52. Japan Exosome Therapy, by Type USD Million (2016-2021)
  • Table 53. Japan Exosome Therapy, by Application USD Million (2016-2021)
  • Table 54. Japan Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 55. Japan Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 56. Japan Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 57. India Exosome Therapy, by Type USD Million (2016-2021)
  • Table 58. India Exosome Therapy, by Application USD Million (2016-2021)
  • Table 59. India Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 60. India Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 61. India Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 62. South Korea Exosome Therapy, by Type USD Million (2016-2021)
  • Table 63. South Korea Exosome Therapy, by Application USD Million (2016-2021)
  • Table 64. South Korea Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 65. South Korea Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 66. South Korea Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 67. Australia Exosome Therapy, by Type USD Million (2016-2021)
  • Table 68. Australia Exosome Therapy, by Application USD Million (2016-2021)
  • Table 69. Australia Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 70. Australia Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 71. Australia Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 72. Rest of Asia-Pacific Exosome Therapy, by Type USD Million (2016-2021)
  • Table 73. Rest of Asia-Pacific Exosome Therapy, by Application USD Million (2016-2021)
  • Table 74. Rest of Asia-Pacific Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 75. Rest of Asia-Pacific Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 76. Rest of Asia-Pacific Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 77. Europe Exosome Therapy, by Country USD Million (2016-2021)
  • Table 78. Europe Exosome Therapy, by Type USD Million (2016-2021)
  • Table 79. Europe Exosome Therapy, by Application USD Million (2016-2021)
  • Table 80. Europe Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 81. Europe Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 82. Europe Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 83. Germany Exosome Therapy, by Type USD Million (2016-2021)
  • Table 84. Germany Exosome Therapy, by Application USD Million (2016-2021)
  • Table 85. Germany Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 86. Germany Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 87. Germany Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 88. France Exosome Therapy, by Type USD Million (2016-2021)
  • Table 89. France Exosome Therapy, by Application USD Million (2016-2021)
  • Table 90. France Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 91. France Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 92. France Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 93. Italy Exosome Therapy, by Type USD Million (2016-2021)
  • Table 94. Italy Exosome Therapy, by Application USD Million (2016-2021)
  • Table 95. Italy Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 96. Italy Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 97. Italy Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 98. United Kingdom Exosome Therapy, by Type USD Million (2016-2021)
  • Table 99. United Kingdom Exosome Therapy, by Application USD Million (2016-2021)
  • Table 100. United Kingdom Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 101. United Kingdom Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 102. United Kingdom Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 103. Netherlands Exosome Therapy, by Type USD Million (2016-2021)
  • Table 104. Netherlands Exosome Therapy, by Application USD Million (2016-2021)
  • Table 105. Netherlands Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 106. Netherlands Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 107. Netherlands Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 108. Rest of Europe Exosome Therapy, by Type USD Million (2016-2021)
  • Table 109. Rest of Europe Exosome Therapy, by Application USD Million (2016-2021)
  • Table 110. Rest of Europe Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 111. Rest of Europe Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 112. Rest of Europe Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 113. MEA Exosome Therapy, by Country USD Million (2016-2021)
  • Table 114. MEA Exosome Therapy, by Type USD Million (2016-2021)
  • Table 115. MEA Exosome Therapy, by Application USD Million (2016-2021)
  • Table 116. MEA Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 117. MEA Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 118. MEA Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 119. Middle East Exosome Therapy, by Type USD Million (2016-2021)
  • Table 120. Middle East Exosome Therapy, by Application USD Million (2016-2021)
  • Table 121. Middle East Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 122. Middle East Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 123. Middle East Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 124. Africa Exosome Therapy, by Type USD Million (2016-2021)
  • Table 125. Africa Exosome Therapy, by Application USD Million (2016-2021)
  • Table 126. Africa Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 127. Africa Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 128. Africa Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 129. North America Exosome Therapy, by Country USD Million (2016-2021)
  • Table 130. North America Exosome Therapy, by Type USD Million (2016-2021)
  • Table 131. North America Exosome Therapy, by Application USD Million (2016-2021)
  • Table 132. North America Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 133. North America Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 134. North America Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 135. United States Exosome Therapy, by Type USD Million (2016-2021)
  • Table 136. United States Exosome Therapy, by Application USD Million (2016-2021)
  • Table 137. United States Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 138. United States Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 139. United States Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 140. Canada Exosome Therapy, by Type USD Million (2016-2021)
  • Table 141. Canada Exosome Therapy, by Application USD Million (2016-2021)
  • Table 142. Canada Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 143. Canada Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 144. Canada Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 145. Mexico Exosome Therapy, by Type USD Million (2016-2021)
  • Table 146. Mexico Exosome Therapy, by Application USD Million (2016-2021)
  • Table 147. Mexico Exosome Therapy, by Therapy USD Million (2016-2021)
  • Table 148. Mexico Exosome Therapy, by Exosome Type USD Million (2016-2021)
  • Table 149. Mexico Exosome Therapy, by End-User USD Million (2016-2021)
  • Table 150. Exosome Therapy: by Type(USD/Units)
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Exosome Therapy: by Type(USD Million)
  • Table 161. Exosome Therapy Instrument , by Region USD Million (2022-2027)
  • Table 162. Exosome Therapy Reagent , by Region USD Million (2022-2027)
  • Table 163. Exosome Therapy Software , by Region USD Million (2022-2027)
  • Table 164. Exosome Therapy: by Application(USD Million)
  • Table 165. Exosome Therapy Diagnostic , by Region USD Million (2022-2027)
  • Table 166. Exosome Therapy Therapeutic , by Region USD Million (2022-2027)
  • Table 167. Exosome Therapy: by Therapy(USD Million)
  • Table 168. Exosome Therapy Immunotherapy , by Region USD Million (2022-2027)
  • Table 169. Exosome Therapy Chemotherapy , by Region USD Million (2022-2027)
  • Table 170. Exosome Therapy Gene Therapy , by Region USD Million (2022-2027)
  • Table 171. Exosome Therapy: by Exosome Type(USD Million)
  • Table 172. Exosome Therapy Natural Exosome , by Region USD Million (2022-2027)
  • Table 173. Exosome Therapy Hybrid Exosome , by Region USD Million (2022-2027)
  • Table 174. Exosome Therapy: by End-User(USD Million)
  • Table 175. Exosome Therapy Cancer Institute , by Region USD Million (2022-2027)
  • Table 176. Exosome Therapy Hospital , by Region USD Million (2022-2027)
  • Table 177. Exosome Therapy Diagnostic Center , by Region USD Million (2022-2027)
  • Table 178. Exosome Therapy Others , by Region USD Million (2022-2027)
  • Table 179. South America Exosome Therapy, by Country USD Million (2022-2027)
  • Table 180. South America Exosome Therapy, by Type USD Million (2022-2027)
  • Table 181. South America Exosome Therapy, by Application USD Million (2022-2027)
  • Table 182. South America Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 183. South America Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 184. South America Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 185. Brazil Exosome Therapy, by Type USD Million (2022-2027)
  • Table 186. Brazil Exosome Therapy, by Application USD Million (2022-2027)
  • Table 187. Brazil Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 188. Brazil Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 189. Brazil Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 190. Argentina Exosome Therapy, by Type USD Million (2022-2027)
  • Table 191. Argentina Exosome Therapy, by Application USD Million (2022-2027)
  • Table 192. Argentina Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 193. Argentina Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 194. Argentina Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 195. Rest of South America Exosome Therapy, by Type USD Million (2022-2027)
  • Table 196. Rest of South America Exosome Therapy, by Application USD Million (2022-2027)
  • Table 197. Rest of South America Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 198. Rest of South America Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 199. Rest of South America Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 200. Asia Pacific Exosome Therapy, by Country USD Million (2022-2027)
  • Table 201. Asia Pacific Exosome Therapy, by Type USD Million (2022-2027)
  • Table 202. Asia Pacific Exosome Therapy, by Application USD Million (2022-2027)
  • Table 203. Asia Pacific Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 204. Asia Pacific Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 205. Asia Pacific Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 206. China Exosome Therapy, by Type USD Million (2022-2027)
  • Table 207. China Exosome Therapy, by Application USD Million (2022-2027)
  • Table 208. China Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 209. China Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 210. China Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 211. Japan Exosome Therapy, by Type USD Million (2022-2027)
  • Table 212. Japan Exosome Therapy, by Application USD Million (2022-2027)
  • Table 213. Japan Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 214. Japan Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 215. Japan Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 216. India Exosome Therapy, by Type USD Million (2022-2027)
  • Table 217. India Exosome Therapy, by Application USD Million (2022-2027)
  • Table 218. India Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 219. India Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 220. India Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 221. South Korea Exosome Therapy, by Type USD Million (2022-2027)
  • Table 222. South Korea Exosome Therapy, by Application USD Million (2022-2027)
  • Table 223. South Korea Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 224. South Korea Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 225. South Korea Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 226. Australia Exosome Therapy, by Type USD Million (2022-2027)
  • Table 227. Australia Exosome Therapy, by Application USD Million (2022-2027)
  • Table 228. Australia Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 229. Australia Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 230. Australia Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 231. Rest of Asia-Pacific Exosome Therapy, by Type USD Million (2022-2027)
  • Table 232. Rest of Asia-Pacific Exosome Therapy, by Application USD Million (2022-2027)
  • Table 233. Rest of Asia-Pacific Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 234. Rest of Asia-Pacific Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 235. Rest of Asia-Pacific Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 236. Europe Exosome Therapy, by Country USD Million (2022-2027)
  • Table 237. Europe Exosome Therapy, by Type USD Million (2022-2027)
  • Table 238. Europe Exosome Therapy, by Application USD Million (2022-2027)
  • Table 239. Europe Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 240. Europe Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 241. Europe Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 242. Germany Exosome Therapy, by Type USD Million (2022-2027)
  • Table 243. Germany Exosome Therapy, by Application USD Million (2022-2027)
  • Table 244. Germany Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 245. Germany Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 246. Germany Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 247. France Exosome Therapy, by Type USD Million (2022-2027)
  • Table 248. France Exosome Therapy, by Application USD Million (2022-2027)
  • Table 249. France Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 250. France Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 251. France Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 252. Italy Exosome Therapy, by Type USD Million (2022-2027)
  • Table 253. Italy Exosome Therapy, by Application USD Million (2022-2027)
  • Table 254. Italy Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 255. Italy Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 256. Italy Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 257. United Kingdom Exosome Therapy, by Type USD Million (2022-2027)
  • Table 258. United Kingdom Exosome Therapy, by Application USD Million (2022-2027)
  • Table 259. United Kingdom Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 260. United Kingdom Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 261. United Kingdom Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 262. Netherlands Exosome Therapy, by Type USD Million (2022-2027)
  • Table 263. Netherlands Exosome Therapy, by Application USD Million (2022-2027)
  • Table 264. Netherlands Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 265. Netherlands Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 266. Netherlands Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 267. Rest of Europe Exosome Therapy, by Type USD Million (2022-2027)
  • Table 268. Rest of Europe Exosome Therapy, by Application USD Million (2022-2027)
  • Table 269. Rest of Europe Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 270. Rest of Europe Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 271. Rest of Europe Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 272. MEA Exosome Therapy, by Country USD Million (2022-2027)
  • Table 273. MEA Exosome Therapy, by Type USD Million (2022-2027)
  • Table 274. MEA Exosome Therapy, by Application USD Million (2022-2027)
  • Table 275. MEA Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 276. MEA Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 277. MEA Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 278. Middle East Exosome Therapy, by Type USD Million (2022-2027)
  • Table 279. Middle East Exosome Therapy, by Application USD Million (2022-2027)
  • Table 280. Middle East Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 281. Middle East Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 282. Middle East Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 283. Africa Exosome Therapy, by Type USD Million (2022-2027)
  • Table 284. Africa Exosome Therapy, by Application USD Million (2022-2027)
  • Table 285. Africa Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 286. Africa Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 287. Africa Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 288. North America Exosome Therapy, by Country USD Million (2022-2027)
  • Table 289. North America Exosome Therapy, by Type USD Million (2022-2027)
  • Table 290. North America Exosome Therapy, by Application USD Million (2022-2027)
  • Table 291. North America Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 292. North America Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 293. North America Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 294. United States Exosome Therapy, by Type USD Million (2022-2027)
  • Table 295. United States Exosome Therapy, by Application USD Million (2022-2027)
  • Table 296. United States Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 297. United States Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 298. United States Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 299. Canada Exosome Therapy, by Type USD Million (2022-2027)
  • Table 300. Canada Exosome Therapy, by Application USD Million (2022-2027)
  • Table 301. Canada Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 302. Canada Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 303. Canada Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 304. Mexico Exosome Therapy, by Type USD Million (2022-2027)
  • Table 305. Mexico Exosome Therapy, by Application USD Million (2022-2027)
  • Table 306. Mexico Exosome Therapy, by Therapy USD Million (2022-2027)
  • Table 307. Mexico Exosome Therapy, by Exosome Type USD Million (2022-2027)
  • Table 308. Mexico Exosome Therapy, by End-User USD Million (2022-2027)
  • Table 309. Exosome Therapy: by Type(USD/Units)
  • Table 310. Research Programs/Design for This Report
  • Table 311. Key Data Information from Secondary Sources
  • Table 312. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Exosome Therapy: by Type USD Million (2016-2021)
  • Figure 5. Global Exosome Therapy: by Application USD Million (2016-2021)
  • Figure 6. Global Exosome Therapy: by Therapy USD Million (2016-2021)
  • Figure 7. Global Exosome Therapy: by Exosome Type USD Million (2016-2021)
  • Figure 8. Global Exosome Therapy: by End-User USD Million (2016-2021)
  • Figure 9. South America Exosome Therapy Share (%), by Country
  • Figure 10. Asia Pacific Exosome Therapy Share (%), by Country
  • Figure 11. Europe Exosome Therapy Share (%), by Country
  • Figure 12. MEA Exosome Therapy Share (%), by Country
  • Figure 13. North America Exosome Therapy Share (%), by Country
  • Figure 14. Global Exosome Therapy: by Type USD/Units (2016-2021)
  • Figure 15. Global Exosome Therapy share by Players 2021 (%)
  • Figure 16. Global Exosome Therapy share by Players (Top 3) 2021(%)
  • Figure 17. Global Exosome Therapy share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Sistemic Ltd Aethlon Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Sistemic Ltd Aethlon Medical, Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Exosome Diagnostic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Exosome Diagnostic, Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Malvern Instruments Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Malvern Instruments Ltd (United Kingdom) Revenue: by Geography 2021
  • Figure 27. System Biosciences, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. System Biosciences, Inc (United States) Revenue: by Geography 2021
  • Figure 29. NX Pharmagen (United States) Revenue, Net Income and Gross profit
  • Figure 30. NX Pharmagen (United States) Revenue: by Geography 2021
  • Figure 31. Capricor Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Capricor Therapeutics, Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Exiqon A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 34. Exiqon A/S (Denmark) Revenue: by Geography 2021
  • Figure 35. NanoSomix, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. NanoSomix, Inc (United States) Revenue: by Geography 2021
  • Figure 37. Global Exosome Therapy: by Type USD Million (2022-2027)
  • Figure 38. Global Exosome Therapy: by Application USD Million (2022-2027)
  • Figure 39. Global Exosome Therapy: by Therapy USD Million (2022-2027)
  • Figure 40. Global Exosome Therapy: by Exosome Type USD Million (2022-2027)
  • Figure 41. Global Exosome Therapy: by End-User USD Million (2022-2027)
  • Figure 42. South America Exosome Therapy Share (%), by Country
  • Figure 43. Asia Pacific Exosome Therapy Share (%), by Country
  • Figure 44. Europe Exosome Therapy Share (%), by Country
  • Figure 45. MEA Exosome Therapy Share (%), by Country
  • Figure 46. North America Exosome Therapy Share (%), by Country
  • Figure 47. Global Exosome Therapy: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Sistemic Ltd Aethlon Medical, Inc. (United States)
  • Exosome Diagnostic, Inc. (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Malvern Instruments Ltd (United Kingdom)
  • System Biosciences, Inc (United States)
  • NX Pharmagen (United States)
  • Capricor Therapeutics, Inc. (United States)
  • Exiqon A/S (Denmark)
  • NanoSomix, Inc (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation